Redhill Biopharma rises on new U.S. patent for COVID drug
19/10/2022 15:00
** U.S.-listed shares of Redhill Biopharma RDHL.O up 66%
at 77 cents
** Co's drug opaganib receives new U.S. method of use patent
for treatment of diseases caused by COVID in patients with
pneumonia and receiving supplemental oxygen urn:newsml:reuters.com:*:nPn25bKGwa
** New patent expires in 2041
** Late-stage development of opaganib is ongoing, pending
Phase 3 trial design regulatory approvals and securing of
external funding
** More than 25 mln shares change hands, 14 times the
stock's 25-day average moving volume
** RDHL down 65% YTD
(Reporting by Nandhini Srinivasan in Bengaluru)
((nandhini.srinivasan@thomsonreuters.com))